Heart Test Laboratories Inc

NASDAQ:HSCS   3:59:51 PM EDT
1.18
-0.08 (-6.35%)
Earnings Announcements

Heart Test Laboratories Inc Says On Track For MyoVista FDA De Novo Resubmission In Current Fiscal Year

Published: 09/13/2022 13:26 GMT
Heart Test Laboratories Inc (HSCS) - Heart Test Laboratories Inc - Remains on Track for Myovista® FDA De Novo Resubmission in Current Fiscal Year.
Heart Test Laboratories Inc - Nearing Completion of Patient Recruitment in FDA Pivotal Clinical Validation Study of Myovista®.
Heart Test-continues to Carefully Manage Expenses & Believes Has Sufficient Capital to Support Operations Beyond Resubmission for FDA De Novo Clearance.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be $0.00

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.35

More details on our Analysts Page.